News

Mar 27, 2023SR One Closes Second Venture Fund at $600M
Aug 9, 2024ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Jul 24, 2024Dren Bio announces strategic collaboration with Novartis to develop novel targeted myeloid engagers for cancer
Dec 8, 2023CRISPR Therapeutics and Vertex announce US FDA approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

11/20/2024Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
11/18/2024Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing
11/14/2024Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
11/09/2024ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
10/08/2024Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
10/01/2024Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director
09/12/2024Oruka Therapeutics Announces $200 Million Private Placement
09/12/2024Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
08/26/2024EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
08/12/2024Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
08/12/2024FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
08/09/2024ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
08/06/2024Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
07/30/2024ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
07/24/2024Dren Bio announces strategic collaboration with Novartis to develop novel targeted myeloid engagers for cancer
07/18/2024Rezo Therapeutics Appoints Cristiana Guiducci, Ph.D., as Chief Scientific Officer
07/16/2024Nkarta announces leadership updates, appoints Nadir Mahmood as President
07/16/2024Asceneuron secures $100M Series C Financing to advance groundbreaking therapeutics in neurodegenerative diseases
07/08/2024Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
07/01/2024Zenas BioPharma appoints Orlando Oliveira as Chief Commercial Officer
06/28/2024ARS Pharmaceuticals announces EURneffy (adrenaline nasal spray) recommended for approval by CHMP for emergency treatment of allergic reactions (anaphylaxis
06/27/2024Nkarta initiates clinical trial of NKX019 in lupus nephritis with first patient in screening and announces pipeline expansion to additional autoimmune indications
06/27/2024Alumis announces pricing of initial public offering
06/14/2024Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
06/13/2024Nkarta adds experienced leader in autoimmune R&D, George Vratsanos, M.D., FACR, to board of directors
05/23/2024CRISPR Therapeutics strengthens executive leadership team with key appointments
05/20/2024Avalyn presents clinical data on AP01 for pulmonary fibrosis, including long- term efficacy and imaging biomarker data, at ATS 2024
05/09/2024Arcellx and Kite continue momentum with advances in anito-cel multiple myeloma program
05/07/2024Zenas BioPharma announces upsized $200M Series C Financing to advance mid- and late- stage immunology- focused clinical development programs
05/01/2024Avalyn bolsters leadership team with the appointment of Douglas Carlson as CFO and CBO
04/30/2024Alumis announces first participant dosed in Ph1 clinical trial of CNS penetrant allosteric TYK2 inhibitor A-005
04/15/2024Pulmocide announces successful results from the OPERA-S Study: a Ph2 safety study with inhaled opelconazole
04/04/2024Odyssey Therapeutics announces strategic collaboration to advance AI- driven small molecule drug discovery
04/03/2024ARS Pharma submits response to FDA complete response letter for neffy® (epinephrine nasal spray)
04/02/2024Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry
04/02/2024ADARx Pharmaceuticals appoints Dr. Chris Storgard as Chief Medical Officer
03/26/2024Avenzo Therapeutics announces $150M oversubscribed financing to advance emerging oncology pipeline
03/25/2024Nkarta announces pricing of $240M underwritten offering
03/13/2024CRISPR Therapeutics proposes new appointment to the board of directors
03/12/2024Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
03/09/2024Alumis presents positive data from Ph2 clinical trial of ESK-001, an oral allosteric TYK2 inhibitor for the treatment of plaque psoriasis at AAD Annual Meeting
03/06/2024Asceneuron expands scientific advisory board with world leading experts in neurodegenerative diseases
03/06/2024Alumis announces upsized $259M Series C financing to advance clinical- stage pipeline of oral therapies designed to address immune dysfunction
02/29/2024FORE Biotherapeutics names William R. Hinshaw as CEO
02/20/2024ARS Pharma announces favorable topline results from repeat dosing study of neffy® (Epinephrine Nasal Spray) under nasal allergen challenge conditions, readies data for response to FDA's complete response letter
02/13/2024CRISPR Therapeutics announces $280M registered direct offering
02/08/2024Renalys Pharma Is Launched To Bring New Innovative Medicines To Patients In Japan and Other Countries In Asia
01/08/2024Simcha Therapeutics announces license & option agreement to develop novel decoy- resistant IL-18 for use in cell therapy applications
01/04/2024Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best- in- class clinical stage CDK2 inhibitor from Allorion Therapeutics
12/08/2023CRISPR Therapeutics and Vertex announce US FDA approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
12/05/2023Odyssey Therapeutics announces $101M Series C
11/16/2023CRISPR Therapeutics and Vertex announce authorization of the first CRISPR/Cas9 Gene- Edited Therapy, CASGEVY™, by the UK MHRA
11/15/2023US FDA approves Bristol- Myers Squibb's (BMY.N) lung cancer drug that was acquired as part of the company's $4.1B buyout of Turning Point Therapeutics (TPTX)
11/15/2023Arcellx and Kite announce expansion in strategic partnership
10/30/2023Dren Bio appoints Amit Mehta as Chief Operating Officer and Chief Business Officer
09/27/2023Avalyn Raises $175M in oversubscribed Series C financing to advance inhaled pulmonary fibrosis programs into later stage clinical studies
09/20/2023Rezo Therapeutics appoints Nadir Mahmood as CEO
09/06/2023Nimbus Therapeutics secures $210M in private financing
08/23/2023FORE Biotherapeutics announces $75M in Series D and CEO Transition
08/09/2023ADARx Pharmaceuticals announces oversubscribed $200M Series C
07/06/2023Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)
07/05/2023Nkarta appoints Alyssa Levin CBO and CFO
06/08/2023FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia
04/11/2023HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B
04/05/2023Simcha Therapeutics announces clinical trial collaboration with Merck to evaluate ST-067 in combination with KEYTRUDA® (Pembrolizumab)
03/27/2023SR One Closes Second Venture Fund at $600M
02/14/2023Mineralys Therapeutics prices $221M IPO
01/20/2023ADARx Pharmaceuticals raises $46M in Series B-1 and appoints Dr. Lorence Kim to Board of Directors
01/09/2023ADARx Pharmaceuticals appoints Robert MacLeod as CSO
01/05/2023Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics
01/03/2023HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B
12/13/2022Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments
12/09/2022Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma
12/06/2022HotSpot Therapeutics launches strategic collaboration with AbbVie to further expand immunology pipeline
11/30/2022Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor
11/17/2022Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A
11/08/2022ARS Pharmaceuticals closes merger with Silverback Therapeutics and currently has over $280M in cash
10/26/2022Nimbus Therapeutics appoints Nathalie Franchimont as CMO
10/13/2022Odyssey Therapeutics raises $168M in Series B
10/11/2022Nimbus Therapeutics announces research collaboration and license agreement with Lilly
09/28/2022ADARx Pharmaceuticals appoints Christopher Prentiss as CFO
09/12/2022Nimbus Therapeutics closes $125M in private financing
08/16/2022Simcha Therapeutics accelerates growth with key leadership appointments, expanded research and option agreement with Yale School of Medicine
08/11/2022PsiOxus Therapetuics appoints Howard Davis as CEO
08/04/2022MiroBio to be acquired by Gilead Sciences for $405M
07/25/2022HotSpot Therapeutics appoints Paul Thibodeau as CBO
07/21/2022ARS Pharmaceuticals and Silverback Therapeutics announces merger
07/19/2022HotSpot Therapeutics appoints Jose Carmona to Board of Directors
07/05/2022Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B
06/29/2022MiroBio raises $97M in Series B
06/21/2022Arcellx appoints Maryam Abdul-Kareem as General Counsel
06/21/2022Arcellx raises $128M in follow-on financing
06/14/2022Dren Bio raises $65M in Series B
06/11/2022CRISPR Therapeutics presents positive results from its Ph1 COBALT™-LYM trial of CTX130™ in relapsed or refractory T cell malignancies
06/11/2022CRISPR Therapeutics and Vertex presents new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel)
06/09/2022Ancora Biotech raises $60M in Series A
06/08/2022Mineralys Therapeutics raises $118M in Series B
06/05/2022eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial
06/03/2022Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B
06/03/2022Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial
05/24/2022Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development
05/23/2022Arcellx appoints Michelle Gilson as CFO
05/19/2022Odyssey Therapeutics appoints Jeffrey M. Leiden as Board Chair
05/16/2022CRISPR Therapeutics appoints Phuong Khanh Morrow as CMO
05/16/2022Arcellx appoints Olivia Ware to Board of Directors
05/10/2022Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform
04/28/2022Nkarta Therapeutics raises $230M in follow-on financing
04/25/2022BioTheryX appoints Jeff Caravella as CFO
04/25/2022Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs
04/12/2022CRISPR Therapeutics appoints Maria Fardis to Board of Directors
04/05/2022ARS Pharmaceuticals appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as CFO
03/25/2022Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting
03/08/2022MiroBio continues expansion of executive leadership team
02/23/2022BioTheryX appoints Nancy Miller- Rich as Board Chair
02/16/2022eFFECTOR Therapeutics appoints Kristen Harrington-Smith to Board of Directors
02/10/2022Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease
02/09/2022ARS Pharmaceuticals expands executive leadership team
02/09/2022Decibel Therapeutics reports on continued progress of lead gene therapy product candidate DB-OTO
02/08/2022Arcellx prices $142.3M IPO
02/02/2022CRISPR Therapeutics and ViaCyte announce first patient dosed in Ph1 clinical trial
02/02/2022Nimbus Therapeutics shares update on discovery efforts in computational chemistry and expands leadership team
02/01/2022Design Therapeutics appoints Jae Kim as CMO
01/27/2022Simcha Therapeutics raises $40M in Series B
01/26/2022BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188
01/25/2022ADARx Pharmaceuticals expands leadership team
01/20/2022BioTheryX appoints Sahm Nasseri as CBO
01/20/2022Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602
01/20/2022Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer
01/19/2022Second Genome appoints Joseph Dal Porto as CSO
01/11/2022Dren Bio announces research collaboration and license agreement with Pfizer
01/10/2022HotSpot Therapeutics and Caris Life Sciences announce collaboration
01/06/2022Odyssey Therapeutics acquires Rahko
01/06/2022Nimbus Therapeutics announces expansion of oral allosteric TYK2 inhibitor program
01/05/2022Bicycle Therapeutics announces continued clinical progress and updates to management team
01/05/2022ADARx Pharmaceuticals appoints Dr. Hubert Chen as CMO
12/20/2021Second Genome granted U.S. patent for proteins for the treatment or prevention of epithelial barrier function disorders
12/16/2021Nkarta receives U.S. FDA orphan drug designation for NKX101 for treatment of patients with AML
12/16/2021Palleon Pharmaceuticals appoints Denis Patrick to its Board of Directors
12/13/2021Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial
12/08/2021Nomic Bio raises $17M in Series A
12/08/2021Tranquis Therapeutics announces initiation of Ph1 study of TQS-168
12/07/2021Odyssey Therapeutics raises $218M in Series A
12/06/2021Pulmocide receives $3.5M investment from the Cystic Fibrosis Foundation
11/29/2021HotSpot Therapeutics raises $100M in Series C
11/22/2021CRISPR Therapeutics announces FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to CTX110™
11/09/2021Palleon presents data on sialoglycan degradation platform that enhances anti-tumor T-cell immunity
11/03/2021Tranquis Therapeutics presents positive preclinical data on TQS-168 for the treatment of ALS
11/02/2021Palleon Pharmaceuticals appoints David Johnson to its Board of Directors
11/02/2021BioTheryX receives IND clearance from FDA to proceed with Ph1 Study of BTX-1188
10/28/2021BioTheryX appoints Philippe Drouet as CEO
10/18/2021Bicycle Therapeutics raises $201.3M
10/12/2021CRISPR Therapeutics reports positive results from its Ph1 CARBON Trial of CTX110™
10/07/2021Bicycle Therapeutics announces preliminary results from Ph1 oncology trials
10/04/2021Turning Point Therapeutics granted breakthrough therapy designation for Repotrectinib treatment
09/21/2021MiroBio appoints Dr. Carolin Barth as CEO
09/15/2021PsiOxus Therapeutics to present positive biomarker data at ESMO 2021
09/08/2021ADARx Pharmaceuticals raises $75M in Series B
08/31/2021ARS Pharmaceuticals raises $55M in Series D
08/25/2021eFFECTOR Therapeutics debuts as public company
08/16/2021Turning Point Therapeutics initiates Ph1b/2 combination study
08/06/2021BioTheryX appoints three new members to its Board of Directors
08/04/2021eFFECTOR Therapeutics initiates Zotatifin Ph2a in breast and lung cancers
07/22/2021eFFECTOR Therapeutics doses first COVID- 19 patient in Zotatifin Ph1b trial
07/13/2021Nimbus Therapeutics raises $105M from top investors
07/13/2021Bicycle Therapeutics enters exclusive license and collaboration agreement with Ionis
07/09/2021Morphic Therapeutic new data from positive Ph1 study of MORF-057
06/17/2021Turning Point Therapeutics receives orphan drug designation for TPX-0022 in gastric cancer
06/15/2021CRISPR Therapeutics and Capsida Biotherapeutics announce strategic collaboration
06/09/2021eFFECTOR Therapeutics doses first patient in Ph2b kickstart clinical trial
05/27/2021Pulmocide raises $92M in Series C
05/27/2021eFFECTOR Therapeutics and Locust Walk Acquisition Corp Annouce Merger
05/26/2021Tranquis Therapeutics appoints Frederic Godderis as COO and Jonas Hannestad as CMO
05/25/2021Turning Point Therapeutics appoints Mark Alles to chair its Board of Directors
05/20/2021BioTheryX raises $92M in Series E
05/19/2021Arcellx to present data at ASCO 2021
05/19/2021Fore Biotherapeutics strengthens leadership team
05/06/2021CRISPR Therapeutics and Nkarta announce global collaboration
05/04/2021eFFECTOR Therapeutics and UCSF receive $5M from DARPA for Covid study
04/20/2021CRISPR Therapeutics amends partnership with Vertex Pharmaceuticals
04/19/2021Arcellx appoints Dr. Christopher as CMO and Neeraj Teotia as CCO
04/14/2021PsiOxus Therapeutics and bluebird bio present preclinical data at AACR 2021
04/14/2021HotSpot Therapeutics appoints Timothy Reilly as Chief Development Officer
04/13/2021Arcellx raises $115M in Series C
04/10/2021Bicycle Therapeutics presents preclinical data at AACR 2021
04/01/2021Pandion Therapeutics acquired by Merck for $1.85BN
03/30/2021Design Therapeutics prices $276M IPO
03/18/2021Bicycle Therapeutics appoints Jose-Carlos Gutierrez-Ramos as Board Director
03/11/2021Positive clinical updates of PC945 in lung infections
03/01/2021Positive interim Phase 1 results of oral integrin therapy
02/22/2021Fore Biotherapeutics appoints Dieter Weinand as Board Chairman and Usama Malik as CEO and Board Director
02/22/2021Preclinical data supporting local immune modulation platform
02/11/2021SR One adds Venture Partners to deepen operational expertise
02/11/2021Decibel Therapeutics prices $127M IPO
01/27/2021Narrow River management raises $40M each for two new renal companies
01/27/2021Design Therapeutics raises $125M Series B
01/26/2021Arcellx appoints Rami Elghandour as Chairman and CEO
01/25/2021Second Genome appoints Dr. Susannah Cantrell as CBO and Dr. Preeti Gupta Lal as CSO
01/14/2021Clinical progress across oncology pipeline
01/07/2021eFFECTOR Therapeutics appoints Mike Byrnes as CFO
12/10/2020FDA accepts BLA for Reltecimod
12/08/2020Repotrectinib treatment in TKI naive patients granted FDA breakthrough therapy designation
12/07/2020Cell therapy demonstrates durable responses in multiple myeloma
12/05/2020Update on gene editing for sickle cell disease and beta-thalassemia
12/04/2020Palleon Pharmaceuticals appoints Deepa Pakianathan as Board Director
12/04/2020Morphic Therapeutic appoints Dr. Martin W. Edwards as Board Director
12/03/2020Pandion Therapeutics appoints Katina Dorton as Board Director
11/19/2020SR One Raises $500M; Completes Spinout from GSK
11/17/2020HotSpot Therapeutics appoints Eva Jack as COO
11/09/2020Decibel Therapeutics raises $82M Series D
11/02/2020Mission Therapeutics appoints Dr. Suhail Nurbhai as CMO
10/26/2020Turning Point Therapeutics raises $400M
10/21/2020Early response data with gene edited cell therapy for B-cell malignancies
10/20/2020Nobel Prize in chemistry awarded to CRISPR Therapeutics founder Emmanuelle Charpentier
10/20/2020Design Therapeutics appoints Joao Siffert as CEO
10/16/2020Dren Bio raises $60M Series A
10/15/2020eFFECTOR Therapeutics appoints Premal Patel as CMO
10/14/2020Nimbus Therapeutics raises $60M
10/05/2020Nkarta Therapeutics appoints Nadir Mahmood as CFO/CBO and Alicia J. Hager as Chief Legal Officer
09/21/2020Fore Biotherapeutics raises $57M Series C
09/17/2020Palleon Pharmaceuticals raises $100M Series B
08/19/2020Early interim data from Trident-1, a registrational Phase 2 of Repotrectinib
08/17/2020Principia Biopharma acquired by Sanofi for $3.7BN
07/16/2020Pandion Therapeutics prices $135M IPO
07/10/2020Nkarta Therapeutics prices $290M IPO
07/09/2020Tranquis Therapeutics raises $30M Series A
07/06/2020Mission Therapeutics raises $15M
06/30/2020CRISPR Therapeutics raises $450M
05/29/2020Tomivosertib demonstrates positive Phase 2 results in combination with checkpoint inhibitors for NSCLC patients
05/21/2020HotSpot Therapeutics raises $65M Series B
05/19/2020Pandion Therapeutics appoints John Sundy as CMO
04/06/2020Second Genome and Gilead Sciences announce strategic collaboration
04/01/2020Pandion Therapeutics raises $80M Series B
03/20/2020Design Therapeutics raises $45M Series A
03/05/2020PsiOxus Therapeutics appoints Dr. Tom Lillie as CMO
01/20/2020FDA approves TEPEZZA™ for the treatment of Thyroid Eye Disease